Deals channel feed – Endpoints News

Deals channel feed

How the pandemic helped secure a rare cancer drug for Menarini

6 years ago

Boehringer Ingelheim sharpens retinal strategy, scooping up dry AMD drug from a Swiss team behind Novartis' Beovu

6 years ago

Merck doubles down on Skyhawk's tech to drug RNA, promising $600M per autoimmune, metabolic target

6 years ago

Bluebird takes $200M payout from Bristol Myers as Covid-19, BLA delays force execs to bring out the budget ax

6 years ago

Spun out of George Church's lab, this biotech upstart is mapping the AAV universe for Novartis, Sarepta to gaze

6 years ago

Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal

6 years ago

Amid lab space scarcity, a life sciences complex to rise in South San Francisco hub

6 years ago

'Deeply committed' Jim Wilson pours more of his life's work into Passage Bio — locking in more gene therapy programs, new tech

6 years ago

Stepping on BioMarin's turf, PTC Therapeutics picks up PKU drug for a song

6 years ago

Tetraphase has two suitors, despite struggling market for antibiotics

6 years ago

Boehringer Ingelheim adds second AI partner in a month

6 years ago

AbbVie gets the FTC's divided blessing for its $63B Allergan buyout — freeing Brent Saunders to blaze a new path

6 years ago

Dealmaking spiked to record levels in April as Covid-19 triggered a fever of partnering. But what happens to collaborations in a new world seen through Zoom?

6 years ago

Alexion bags a discount biotech buyout for $1.4B, branching out in new directions from its Soliris franchise

6 years ago

BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases

6 years ago

Menarini bags Stemline and a rare disease drug in $677M buyout. But will a better offer follow?

6 years ago

Amid Covid-19 hunt, Pfizer adds Lyme disease vaccine in $308M deal with Valneva

6 years ago

AstraZeneca vaults to the front of the Covid-19 vaccine race, teaming up to globalize Oxford candidate

6 years ago

Having sold its corporate self, Tocagen auctions off scientific platform to San Diego biotech

6 years ago

Takeda auctions off a $670M portfolio of drugs and manufacturing ops, getting closer to its $10B goal

6 years ago

Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells

6 years ago

Astellas snaps up mitochondria-focused biotech, beefs up drug discovery in budget deal

6 years ago

Esperion strikes Japan deal for 'goldilocks' cholesterol drug, bags $60M cash as pandemic forces virtual US rollout

6 years ago

Novartis eyes a new market with its buyout of a small digital therapeutics player

6 years ago

First page Previous page 92 93 949596 97 98 Next page Last page